Does A Lesion On The Prostate Mean Cancer?

Hearing that you’ve got a lesion on your prostate can be unsettling.

It’s natural to think of the worst, but a lesion doesn’t always mean cancer. In many cases, it turns out to be something far less serious, like inflammation or a harmless growth. 

What is a prostate lesion?

A lesion on the prostate means there’s an area of tissue that looks different from the rest of the gland. It’s not a diagnosis by itself but simply a description of something that appears unusual on a scan, like an MRI or ultrasound.

Lesions vary in size and shape, and that’s what helps doctors decide if they’re likely to be harmless or suspicious.

Some lesions are due to prostatitis, an inflammation that may result from infection. Others appear because of benign prostatic hyperplasia (BPH), a common condition that causes the prostate to enlarge as you age. Only a small portion of lesions turn out to be linked with cancer.

When might a lesion indicate prostate cancer?

Although most prostate lesions aren’t dangerous, some can suggest the presence of prostate cancer.

To determine this, doctors rely on detailed imaging, such as a multiparametric MRI (mpMRI). This type of scan provides a clearer picture of the prostate and highlights areas that may need closer inspection.

Radiologists use a system called PI-RADS (Prostate Imaging Reporting and Data System) to score lesions from 1 to 5. A score of 1 or 2 usually means the area is unlikely to be cancerous, while a 4 or 5 means it’s more suspicious and often needs further testing.

This approach ensures doctors focus only on the areas that genuinely need attention, avoiding unnecessary procedures.

How prostate lesions are investigated

When a lesion looks questionable, doctors may order extra tests to get more information.

A common first step is the prostate-specific antigen (PSA) blood test. High PSA levels might raise suspicion, but it’s not a perfect indicator, since infection or enlargement can also increase PSA.

If imaging and PSA suggest something unusual, the next step might be a biopsy. This involves taking tiny samples of prostate tissue to check under a microscope. Sometimes, doctors use MRI-guided biopsies to target the precise area that looked abnormal on the scan.

This focused approach improves accuracy and reduces discomfort compared to older biopsy methods.

Related read: What Not To Do Before A PSA Blood Test.

Managing worry after finding a lesion

Being told there’s a lesion can make anyone anxious, but it’s worth remembering that most prostate lesions aren’t cancerous. Advances in imaging mean that many harmless findings are now picked up more often simply because scans are more detailed than ever.

Your urologist will explain what your specific results mean, how serious they might be, and what monitoring plan suits you best. Talking through each step can help reduce worry and make things clearer. Try not to assume the worst until all results are confirmed, as many patients later find their lesion was completely benign.

Moving forward with confidence

A lesion on the prostate doesn’t always signal cancer, and many turn out to be non-cancerous changes.

What matters most is accurate diagnosis, proper follow-up, and expert guidance. Regular reviews with your doctor ensure that if something does develop, it’s found early and managed effectively. 

With reassurance and ongoing care, you can move forward confidently knowing your prostate health is being looked after. In most cases, early checks and open communication with your urologist lead to excellent outcomes and peace of mind.

Picture of Maneesh Ghei
Maneesh Ghei
Mr Maneesh Ghei MS MRCSEd MD (UCL) FRCS (Urol) is a highly experienced Consultant Urological Surgeon and founder of Urocare London, with over three decades of practice in both NHS and private settings across the capital. As Lead Cancer Clinician at Whittington Hospital, Archway, he chairs the multidisciplinary urology cancer meeting, overseeing patient care from diagnosis through to the latest minimally invasive treatments. A pioneer in complex endourology and stone disease management, Mr Ghei led the UK’s first randomised, double-blind trial of intradetrusor botulinum toxin for refractory overactive bladder. He holds an MBBS and MS in General Surgery from India, an MD from University College London, and undertook advanced fellowships in stone disease and laparoscopic surgery, culminating in his Fellowship of the Royal College of Surgeons (Urology). Committed to education and research, he supervises doctoral work in focal therapies and cryotherapy for prostate cancer and champions public awareness through annual Movember fundraising.
Scroll to Top